A Long-term Observational Study in Participants Who Have Received PBGENE-HBV
← catalyst calendarNCT07254208 · readout ≤ 4,913 d
Sponsored by Precision BioSciences, Inc. (industry) · DTIL — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
45estimated
Sites
4
Countries
Hong Kong, Moldova, New Zealand +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-25 | actual | When the study began enrolling |
| Primary completion | Jan 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic HBV Infection
Intervention
- Biological: PBGENE-HBV
Primary outcome
what the primary-completion date above is the date OFSafety to assess frequency, severity, and outcome of delayed adverse events
measured 15 years
Permalink · DTIL's whole pipeline · Catalyst calendar · Every registered study · What changed